4//SEC Filing
Alexza Pharmaceuticals Inc. 4
Accession 0001209191-16-129018
CIK 0001344413operating
Filed
Jun 20, 8:00 PM ET
Accepted
Jun 21, 3:56 PM ET
Size
21.3 KB
Accession
0001209191-16-129018
Insider Transaction Report
Form 4
Kamemoto Edwin S
EVP, R&D and Quality
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2016-06-21−15,000→ 0 totalExercise: $3.47From: 2013-07-26Exp: 2022-07-25→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−43,750→ 0 totalExercise: $4.42From: 2014-03-29Exp: 2024-05-20→ Common Stock (43,750 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−125,000→ 0 totalExercise: $1.08From: 2015-08-21Exp: 2025-07-21→ Common Stock (125,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−24,000→ 0 totalExercise: $4.57From: 2015-06-27Exp: 2024-06-26→ Common Stock (24,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−9,999→ 0 totalExercise: $15.30From: 2011-07-28Exp: 2021-07-27→ Commmon Stock (9,999 underlying) - Disposition from Tender
Common Stock
2016-06-21−9,112→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2016-06-21−35,000→ 0 totalExercise: $1.95From: 2016-04-28Exp: 2025-04-27→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (right to buy
2016-06-21−5,000→ 0 totalExercise: $3.47From: 2013-07-26Exp: 2022-07-25→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Includes 6,250 previously reported shares issued as restricted stock units ("RSUs") under the Issuer's 2005 Equity Incentive Plan (the "Plan"). Per Section 3.4(b) of the Agreement and Plan of Merger, dated 5/9/16, among the Issuer, Grupo Ferrer Internactional, S.A. and Ferrer Pharma Inc. (the "Agreement), each RSU outstanding immediately prior to the Offer Closing (as defined in the Agreement) became fully vested immediately prior to the Offer Closing.
- [F2]Per the terms of the Agreement and the Offer (as defined in the Agreement), each share of the Issuer's common stock was tendered for $0.90 per share in cash, without interest and less any required withholding taxes, plus one contractual contingent value right per share ("CVR") (as defined in the Agreement).
- [F3]Disposed of per Section 3.4(a) of the Agreement, whereby each option that was outstanding immediately prior to the Offer Closing (as defined in the Agreement) was cancelled without consideration.
Documents
Issuer
Alexza Pharmaceuticals Inc.
CIK 0001344413
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001344413
Filing Metadata
- Form type
- 4
- Filed
- Jun 20, 8:00 PM ET
- Accepted
- Jun 21, 3:56 PM ET
- Size
- 21.3 KB